Foghorn Therapeutics (FHTX) Projected to Release Quarterly Earnings on Wednesday

Foghorn Therapeutics (NASDAQ:FHTX) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Foghorn Therapeutics to post earnings of ($0.23) per share and revenue of $6.39 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its earnings results on Thursday, August 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.14. The company had revenue of $16.07 million for the quarter, compared to the consensus estimate of $6.80 million. On average, analysts expect Foghorn Therapeutics to post ($0.86) EPS for the current fiscal year and ($0.91) EPS for the next fiscal year.

Foghorn Therapeutics Price Performance

Shares of NASDAQ:FHTX opened at $2.05 on Wednesday. Foghorn Therapeutics has a fifty-two week low of $1.79 and a fifty-two week high of $7.61. The business has a 50-day moving average of $3.89 and a two-hundred day moving average of $4.78.

Analyst Ratings Changes

Several research firms recently weighed in on FHTX. Stifel Nicolaus set a $5.00 target price on Foghorn Therapeutics in a report on Thursday, October 1st. Wall Street Zen upgraded Foghorn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Evercore set a $3.00 price objective on shares of Foghorn Therapeutics and gave the stock an “in-line” rating in a research note on Tuesday, October 13th. HC Wainwright decreased their price objective on shares of Foghorn Therapeutics from $13.00 to $5.00 and set a “buy” rating for the company in a report on Friday, October 2nd. Finally, Citigroup lowered shares of Foghorn Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Thursday, October 1st. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.14.

About Foghorn Therapeutics

Foghorn Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins.

Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes.